Masimo (MASI) Scheduled to Post Earnings on Tuesday

Masimo (NASDAQ:MASI) will release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Masimo to post earnings of $0.71 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The business had revenue of $548.90 million during the quarter, compared to analyst estimates of $545.69 million. During the same quarter in the previous year, the firm posted $1.32 EPS. The business’s revenue for the quarter was down 11.0% compared to the same quarter last year. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Masimo Price Performance

Shares of NASDAQ MASI opened at $137.00 on Monday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.18 and a quick ratio of 1.22. The firm has a market capitalization of $7.25 billion, a PE ratio of 90.73 and a beta of 0.99. Masimo has a 1-year low of $75.22 and a 1-year high of $188.76. The business’s fifty day moving average price is $136.10 and its two-hundred day moving average price is $118.80.

Insiders Place Their Bets

In other news, Director Craig B. Reynolds sold 40,000 shares of Masimo stock in a transaction on Friday, April 26th. The stock was sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the transaction, the director now directly owns 7,406 shares in the company, valued at approximately $1,008,475.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 9.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $117.00 to $160.00 in a report on Monday, March 25th. StockNews.com upgraded shares of Masimo from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. BTIG Research boosted their price objective on Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. Jefferies Financial Group reissued a “hold” rating and issued a $121.00 price objective (up from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Finally, Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and lifted their target price for the company from $148.00 to $170.00 in a research note on Monday, April 15th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Masimo presently has an average rating of “Hold” and an average price target of $137.43.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.